Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An explanation for SARS-CoV-2 rebound after Paxlovid treatment
Alan S. Perelson, Ruy M. Ribeiro, Tin Phan
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy
Gregory E. Edelstein, Julie Boucau, Rockib Uddin, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 12, pp. 1577-1585
Open Access | Times Cited: 44
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Y.-C. Chung, Ching-Yin Lam, Pak-Hei Tan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8155-8155
Open Access | Times Cited: 9
How robust are estimates of key parameters in standard viral dynamic models?
Carolin Zitzmann, Ruian Ke, Ruy M. Ribeiro, et al.
PLoS Computational Biology (2024) Vol. 20, Iss. 4, pp. e1011437-e1011437
Open Access | Times Cited: 7
A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy
Shadisadat Esmaeili, Katherine Owens, Jessica Wagoner, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
A mathematical model for the within-host (re)infection dynamics of SARS-CoV-2
Lea Schuh, Peter V. Markov, Vladimir M. Veliov, et al.
Mathematical Biosciences (2024) Vol. 371, pp. 109178-109178
Open Access | Times Cited: 6
A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
Zhanwei Du, Lin Wang, Yuan Bai, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 5
3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials
Vitor Martins de Freitas Amorim, Eduardo Pereira Soares, Anielle Salviano de Almeida Ferrari, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 844-844
Open Access | Times Cited: 5
Multi-objective control to schedule therapies for acute viral infections
Mara Pérez, Marcelo Actis, Ignacio José García Sánchez, et al.
Journal of Mathematical Biology (2025) Vol. 90, Iss. 2
Closed Access
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody
Tin Phan, Carolin Zitzmann, Kara W. Chew, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 4, pp. e1011680-e1011680
Open Access | Times Cited: 4
Viral Rebound After Antiviral Treatment: A Mathematical Modeling Study of the Role of Antiviral Mechanism of Action
A. Chiarelli, Hana M. Dobrovolny
Interdisciplinary Sciences Computational Life Sciences (2024) Vol. 16, Iss. 4, pp. 844-853
Closed Access | Times Cited: 3
The kinetics of SARS-CoV-2 infection based on a human challenge study
Sarafa A. Iyaniwura, Ruy M. Ribeiro, Carolin Zitzmann, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 46
Open Access | Times Cited: 3
Making waves: Integrating wastewater surveillance with dynamic modeling to track and predict viral outbreaks
Tin Phan, Samantha Brozak, Bruce Pell, et al.
Water Research (2023) Vol. 243, pp. 120372-120372
Open Access | Times Cited: 8
Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses
Eric A. Meyerowitz, Yijia Li
Clinical Infectious Diseases (2023) Vol. 78, Iss. 4, pp. 908-917
Open Access | Times Cited: 8
3-Chymotrypsin-like Protease (3CLpro): Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials
Vitor Martins de Freitas Amorim, Eduardo Pereira Soares, Anielle Salviano de Almeida Ferrari, et al.
(2024)
Open Access | Times Cited: 2
Rebound of COVID-19 With Nirmatrelvir–Ritonavir Antiviral Therapy
Myron S. Cohen, Elizabeth R. Brown
Annals of Internal Medicine (2023) Vol. 176, Iss. 12, pp. 1672-1673
Open Access | Times Cited: 7
Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
Ioannis Karniadakis, Nikolaos Mazonakis, Constantinos Tsioutis, et al.
Infectious Disease Reports (2023) Vol. 15, Iss. 6, pp. 662-678
Open Access | Times Cited: 6
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
Gregory E. Edelstein, Julie Boucau, Rockib Uddin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
Virus-mediated cell fusion of SARS-CoV-2 variants
Ava Amidei, Hana M. Dobrovolny
Mathematical Biosciences (2024) Vol. 369, pp. 109144-109144
Closed Access | Times Cited: 1
Safety Profile of Paxlovid in the Treatment of COVID-19
Bing Lv, Xin Gao, Guoqiang Zeng, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 9, pp. 666-675
Closed Access | Times Cited: 1
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral rebound
Shadisadat Esmaeili, Katherine Owens, Jessica Wagoner, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody
Tin Phan, Carolin Zitzmann, Kara W. Chew, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Within-host dynamics of antiviral treatment for SARS-CoV-2 infection
Lea Schuh, Peter V. Markov, Ioanna Voulgaridi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Stuck in pandemic uncertainty: a review of the persistent effects of COVID-19 infection in immune-deficient people
Bevin Manuelpillai, Mackenzie Zendt, Emma Chang-Rabley, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 1007-1011
Open Access
Page 1 - Next Page

Scroll to top